Accession Number:

AD1039020

Title:

Intravesical NGF Antisense Therapy Using Lipid Nanoparticle for Interstitial Cystitis

Descriptive Note:

Technical Report,30 Sep 2012,29 Sep 2016

Corporate Author:

Lipella Pharmaceuticals, Inc. Pittsburgh United States

Report Date:

2016-12-01

Pagination or Media Count:

19.0

Abstract:

Interstitial cystitisbladder pain syndrome ICBPS is a debilitating disorder characterized by persistent pelvic pain associated with bladder symptoms including urinary frequency and urgency. Previous studies have indicated that overexpression of nerve growth factor NGF isan important factor in the symptom development of ICBPS. This project evaluates the potential of an anti-NGF bladder drug delivery system as a potential investigational drug product indicated for ICBPS. The investigational drug product is a proprietary liposome NGF-antisense formulation given the development name of LP-11. The project aims included research, manufacture, and nonclinical testing of LP-11. The long-term objective of the research program is to establish new local anti-NGF therapy for the treatment of ICBPS.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE